TY - JOUR
T1 - Natural history of mesenchymal stem cells, from vessel walls to culture vessels
AU - Murray, Iain R.
AU - West, Christopher C.
AU - Hardy, Winters R.
AU - James, Aaron W.
AU - Park, Tea Soon
AU - Nguyen, Alan
AU - Tawonsawatruk, Tulyapruek
AU - Lazzari, Lorenza
AU - Soo, Chia
AU - Péault, Bruno
N1 - Funding Information:
B.P., and C.S. are inventors of perivascular stem cell-related patents filed from UCLA. Dr C.S. is a founder of Scarless Laboratories Inc. which sublicenses perivascular stem cell-related patents from the UC Regents, and who also hold equity in the company. Dr C.S. is also an officer of Scarless Laboratories, Inc. This work was supported by the CIRM Early Translational II Research Award TR2-01821.
PY - 2014/4
Y1 - 2014/4
N2 - Mesenchymal stem/stromal cells (MSCs) can regenerate tissues by direct differentiation or indirectly by stimulating angiogenesis, limiting inflammation, and recruiting tissue-specific progenitor cells. MSCs emerge and multiply in long-term cultures of total cells from the bone marrow or multiple other organs. Such a derivation in vitro is simple and convenient, hence popular, but has long precluded understanding of the native identity, tissue distribution, frequency, and natural role of MSCs, which have been defined and validated exclusively in terms of surface marker expression and developmental potential in culture into bone, cartilage, and fat. Such simple, widely accepted criteria uniformly typify MSCs, even though some differences in potential exist, depending on tissue sources. Combined immunohistochemistry, flow cytometry, and cell culture have allowed tracking the artifactual cultured mesenchymal stem/stromal cells back to perivascular anatomical regions. Presently, both pericytes enveloping microvessels and adventitial cells surrounding larger arteries and veins have been described as possible MSC forerunners. While such a vascular association would explain why MSCs have been isolated from virtually all tissues tested, the origin of the MSCs grown from umbilical cord blood remains unknown. In fact, most aspects of the biology of perivascular MSCs are still obscure, from the emergence of these cells in the embryo to the molecular control of their activity in adult tissues. Such dark areas have not compromised intents to use these cells in clinical settings though, in which purified perivascular cells already exhibit decisive advantages over conventional MSCs, including purity, thorough characterization and, principally, total independence from in vitro culture. A growing body of experimental data is currently paving the way to the medical usage of autologous sorted perivascular cells for indications in which MSCs have been previously contemplated or actually used, such as bone regeneration and cardiovascular tissue repair.
AB - Mesenchymal stem/stromal cells (MSCs) can regenerate tissues by direct differentiation or indirectly by stimulating angiogenesis, limiting inflammation, and recruiting tissue-specific progenitor cells. MSCs emerge and multiply in long-term cultures of total cells from the bone marrow or multiple other organs. Such a derivation in vitro is simple and convenient, hence popular, but has long precluded understanding of the native identity, tissue distribution, frequency, and natural role of MSCs, which have been defined and validated exclusively in terms of surface marker expression and developmental potential in culture into bone, cartilage, and fat. Such simple, widely accepted criteria uniformly typify MSCs, even though some differences in potential exist, depending on tissue sources. Combined immunohistochemistry, flow cytometry, and cell culture have allowed tracking the artifactual cultured mesenchymal stem/stromal cells back to perivascular anatomical regions. Presently, both pericytes enveloping microvessels and adventitial cells surrounding larger arteries and veins have been described as possible MSC forerunners. While such a vascular association would explain why MSCs have been isolated from virtually all tissues tested, the origin of the MSCs grown from umbilical cord blood remains unknown. In fact, most aspects of the biology of perivascular MSCs are still obscure, from the emergence of these cells in the embryo to the molecular control of their activity in adult tissues. Such dark areas have not compromised intents to use these cells in clinical settings though, in which purified perivascular cells already exhibit decisive advantages over conventional MSCs, including purity, thorough characterization and, principally, total independence from in vitro culture. A growing body of experimental data is currently paving the way to the medical usage of autologous sorted perivascular cells for indications in which MSCs have been previously contemplated or actually used, such as bone regeneration and cardiovascular tissue repair.
KW - Blood vessels
KW - Cell therapy
KW - Mesenchymal stem cells
KW - Pericytes
KW - Stem cells
KW - Tissue repair
UR - http://www.scopus.com/inward/record.url?scp=84897114196&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84897114196&partnerID=8YFLogxK
U2 - 10.1007/s00018-013-1462-6
DO - 10.1007/s00018-013-1462-6
M3 - Review article
C2 - 24158496
AN - SCOPUS:84897114196
SN - 1420-682X
VL - 71
SP - 1353
EP - 1374
JO - Cellular and Molecular Life Sciences
JF - Cellular and Molecular Life Sciences
IS - 8
ER -